NEW YORK--(BUSINESS WIRE)--Today, Opentrons Labworks Inc. announced that SoftBank Vision Fund 2* has led a $200 million Series C investment in the company, with participation from Khosla Ventures. Opentrons will use the funding to further invest in its global automated laboratory platform.
“The company has an extremely high value proposition in the laboratory diagnostics and synthetic genomics markets, where its robots and consumables are now fundamental components. We look forward to working with CEO Jonathan Brennan-Badal to help the company accelerate growth and bring new Product commercialization.”
"Biology opens the door to solving many of humanity's grand challenges. For too long, scientists and clinicians have been hamstrung by the slow, expensive, and overly complex laboratory solutions that underpinned their work." Opentrons CEO Jon Brennan-Badal said. "Opentrons' platform provides the key to unlocking its potential. We are doing more R&D, more testing, more biological research to unlock innovation in life sciences and healthcare."
This laboratory platform uniquely integrates the development of laboratory robotics, analysis and operations to create high-quality and cost-effective end solutions. Opentrons uses the platform to provide the following industry-specific laboratory solutions:
"Opentrons is building a disruptive automated laboratory platform designed to transform healthcare and life sciences with vertically integrated, low-cost solutions," said Angela Du, investment director at SoftBank Investment Advisors. "The company has expertise in laboratory diagnostics and synthesis The genomics market has a strong value proposition and its robotics and consumables are now fundamental components of the market. We look forward to working with CEO Jonathan Brennan-Badal to help the company accelerate growth and commercialize new products."
The Series C round will bring significant investment into the Opentrons platform. In particular, the investment will support the development of new robotic tools, an expanded biofoundry, new diagnostic tests and additional diagnostic laboratories. All of these initiatives will lead to better, more affordable solutions for our life sciences and healthcare customers.
OPENTRONS Announces Key New Team Additions to Scale Platform:
About OPENTRONS LABWORKS INC., SUBSIDIARIES AND INVESTORS
*As of the date of this press release, SoftBank Group Corporation has made investments that allow the SoftBank Vision Fund 2 ("SVF 2") to invest in certain portfolio companies. The information contained herein is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. There has been no external closing of SVF 2, and any potential third-party investors should receive further information related to any SVF 2 investment prior to closing.
Contact Information
Greg GreeleyOpentrons Press Teampress@opentrons.com
The experienced service team and strong production support team provide customers with worry-free order services.
